Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

QIAGEN announces broadening of GeneReader NGS System applications into hereditary disease analysis

QGEN

QIAGEN announces broadening of GeneReader NGS System applications into hereditary disease analysis

Delivering valuable insights with solution anchored by GeneReader NGS System and utilizing QIAact target enrichment panels and gold-standard QIAGEN bioinformatics solutions

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today introduced seamless next-generation sequencing (NGS) solutions for a wide range of hereditary diseases on the GeneReader NGS System, the complete Sample to Insight NGS solution for any lab worldwide.

QIAGEN has launched customizable QIAact target enrichment panels for analysis of more than 13 hereditary disease groups. The solutions integrate QIAGEN’s QCI analysis and interpretation solutions, in particular also QIAGEN’s HGMD Human Gene Mutation Database, the leading genomic knowledge base on hereditary diseases, with integrated bioinformatics analysis and interpretation software to deliver clear, actionable reports.

This integrated solution will allow for the analysis of specific sets of genetic hereditary disorders of interest, including inherited cancers, cystic fibrosis, inherited cardiovascular diseases, universal carrier screening and various other hereditary conditions.

“Genetic laboratories are eager to gain deeper insights into a range of hereditary diseases by using the power of NGS technology, but have been held back by the lack of complete workflows and powerful bioinformatics solutions. We are pleased to offer the first complete Sample to Insight solution for analysis of hereditary diseases. Our solution, anchored by the GeneReader NGS System, provides the complete solution that labs need to efficiently and reliably perform genetic analysis,” said Peer M. Schatz, Chief Executive Officer of QIAGEN.

Please find the full press release here

QIAGEN
Investor Relations
John Gilardi
e-mail: ir@QIAGEN.com
+49 2103 29 11711
or
Public Relations
Robert Reitze
e-mail: pr@QIAGEN.com
+49 2103 29 11676



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today